Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued?

Ligand Pharmaceuticals (LGND) drew investor attention after its shares last closed at US$288.83. The biopharma licensor now carries a market value of about US$5.7b, which reflects expectations around its broad portfolio of partnered therapies.

Recent trading hints at momentum building again for Ligand Pharmaceuticals, with a 16.35% 90 day share price return contributing to a 51.93% year to date move and a 74.62% 1 year total shareholder return. The 3 and 5 year total shareholder returns above 200% underline how long term holders have been rewarded as perceptions around its risk and growth profile have shifted.

Scan beyond Ligand Pharmaceuticals and size up other potential breakout candidates across our hand-picked 17 high quality undiscovered gems to see which businesses share similar momentum with strong underlying fundamentals.

Bulls argue Ligand Pharmaceuticals recent surge reflects a robust royalty engine and solid earnings base. Bears see stretched expectations at US$288.83. The valuation work next helps show which side the numbers lean toward.

Most Popular Narrative: 15.7% Undervalued

Ligand Pharmaceuticals most followed valuation story points to a fair value of about $342.82 against the recent $288.83 close, which puts the spotlight firmly on what assumptions drive that gap.

Strong revenue and earnings growth are expected as Ligand broadens its high-margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late-stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long-term cash flow predictability.

Read the complete narrative.

Curious what it would take for that royalty engine to support a higher valuation than many traditional pharma names? The narrative leans heavily on faster top line growth, strong profitability, and a richer earnings multiple than the wider sector. The detailed model walks through how those pieces fit together and which assumptions really move the fair value needle.

Result: Fair Value of $342.82 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, Ligand Pharmaceuticals depends heavily on a handful of royalty assets and remains exposed to drug pricing pressure, which could challenge the optimistic valuation story.

Find out about the key risks to this Ligand Pharmaceuticals narrative.

Another View: What Multiples Say About Ligand Pharmaceuticals

The SWS DCF model views Ligand Pharmaceuticals as trading 32.4% below its estimated fair value of $427.46 at a current price of $288.83. However, the current 29.2x P/E ratio is well above both the US Pharmaceuticals industry average of 16.2x and the 21.8x fair ratio. That gap suggests richer expectations for earnings, so it is worth considering how much of a premium you are comfortable with if sentiment cools.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed mood around Ligand Pharmaceuticals has you torn, move quickly and review the data yourself so you are not simply inheriting someone else’s conviction. A good starting point is to weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ligand Pharmaceuticals?

Do not stop your research with Ligand Pharmaceuticals alone. Broadening your watchlist with other high quality opportunities can help you spot setups before the crowd catches on.

• Target resilient compounding potential by scanning our 49 high quality undervalued stocks that combine quality fundamentals with prices that sit below many investors’ implied expectations.
• Strengthen your capital base with the 6 dividend fortresses that aim to pair income potential with robust underlying businesses.
• Protect against unwanted shocks by filtering for the 82 resilient stocks with low risk scores so you focus on companies with lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com